These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17571366)

  • 1. [Calcium sensitizer agents in heart failure therapy].
    Iwama Y; Takagi A
    Nihon Rinsho; 2007 May; 65 Suppl 5():61-5. PubMed ID: 17571366
    [No Abstract]   [Full Text] [Related]  

  • 2. [Calcium sensitizer: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
    Shinagawa H; Izumi T
    Nihon Rinsho; 2007 May; 65 Suppl 5():57-60. PubMed ID: 17569308
    [No Abstract]   [Full Text] [Related]  

  • 3. [Calcium sensitizers--a new group of drugs that increase myocardium contractility].
    Laine M; Lehtonen L; Nieminen MS
    Duodecim; 2000; 116(20):2181-3. PubMed ID: 12017622
    [No Abstract]   [Full Text] [Related]  

  • 4. What is the in vivo mechanism of action of levosimendan?
    MacGowan GA
    J Card Fail; 2005 Aug; 11(6):482; author reply 482-3. PubMed ID: 16105641
    [No Abstract]   [Full Text] [Related]  

  • 5. Levosimendan: a new option in acute cardiac failure.
    Holley AD; Ziegenfuss M
    Emerg Med Australas; 2006; 18(5-6):505-9. PubMed ID: 17083641
    [No Abstract]   [Full Text] [Related]  

  • 6. Beta blocker therapy, decompensated heart failure, and inotropic interactions: current perspectives.
    Zafrir B; Amir O
    Isr Med Assoc J; 2012 Mar; 14(3):184-9. PubMed ID: 22675861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [If the myofilaments become sensitive: Ca2+-sensitizer for the therapy of heart insufficiency].
    Schwinger RH; Brixius K
    Dtsch Med Wochenschr; 2005 Apr; 130(15):969-73. PubMed ID: 15812725
    [No Abstract]   [Full Text] [Related]  

  • 8. Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: impact on heart failure.
    Kota B; Prasad AS; Economides C; Singh BN
    J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):269-78. PubMed ID: 19087950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ST-segment elevation during levosimendan infusion.
    Barillà F; Giordano F; Jacomelli I; Pellicano M; Dominici T
    J Cardiovasc Med (Hagerstown); 2012 Jul; 13(7):454-6. PubMed ID: 22673026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel biologic mechanisms of levosimendan and its effect on the failing heart.
    Parissis JT; Andreadou I; Bistola V; Paraskevaidis I; Filippatos G; Kremastinos DT
    Expert Opin Investig Drugs; 2008 Aug; 17(8):1143-50. PubMed ID: 18616411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do levosimendan have an adverse effect on platelet function?
    Kaptan K; Beyan C; Ifran A
    Int J Cardiol; 2010 Oct; 144(3):414-5. PubMed ID: 19327852
    [No Abstract]   [Full Text] [Related]  

  • 13. Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers.
    Ukkonen H; Saraste M; Akkila J; Knuuti MJ; Lehikoinen P; Någren K; Lehtonen L; Voipio-Pulkki LM
    Clin Pharmacol Ther; 1997 May; 61(5):596-607. PubMed ID: 9164421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levosimendan: a new dual-action drug in the treatment of acute heart failure.
    Mebazaa A; Erhardt L
    Int J Clin Pract; 2003 Jun; 57(5):410-6. PubMed ID: 12846347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical properties of OR-1259--a positive inotropic and vasodilatory compound with an antiarrhythmic effect.
    Raasmaja A; Talo A; Haikala H; Nissinen E; Lindén IB; Pohto P
    Adv Exp Med Biol; 1992; 311():423. PubMed ID: 1529781
    [No Abstract]   [Full Text] [Related]  

  • 16. [Levosimendan for treatment of heart failure].
    Yasumura Y
    Nihon Rinsho; 2007 May; 65 Suppl 5():169-72. PubMed ID: 17571380
    [No Abstract]   [Full Text] [Related]  

  • 17. Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction.
    Lilleberg J; Sundberg S; Nieminen MS
    J Cardiovasc Pharmacol; 1995; 26 Suppl 1():S63-9. PubMed ID: 8907133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness of levosimendan in patients with predominant right heart failure.
    Poelzl G; Zwick RH; Grander W; Metzler B; Jonetzko P; Frick M; Ulmer H; Pachinger O; Roithinger FX
    Herz; 2008 Jul; 33(5):368-73. PubMed ID: 18773157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral levosimendan in patients with severe chronic heart failure --the PERSIST study.
    Nieminen MS; Cleland JG; Eha J; Belenkov Y; Kivikko M; Põder P; Sarapohja T
    Eur J Heart Fail; 2008 Dec; 10(12):1246-54. PubMed ID: 18945637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.